Also from this source

You just read:

NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference

News provided by

NeuroPhage Pharmaceuticals, Inc.

Jul 19, 2015, 02:00 ET